The therapeutic vaccine company
Our vision is to help people worldwide achieve a healthier, longer, and better-quality life.
As an international biotechnology company, Genetic Immunity, Inc. has been working on immunotherapeutic vaccines for nearly 20 years. Our antigen-specific, plasmid DNA–based therapeutic vaccine offers a platform for treating various types of cancers and viral infections. We provide a solution from vector design to the transdermal application of the vaccine and manufacturing.
Plasmid DNA is a next-generation technological instrument that has opened up new horizons in medicine. Our lead product candidate, DermaVir® is a DNA-based therapeutic vaccine that directs the immune system to actively fight the target disease. Through its mechanism of action, our vaccine naturally evokes antigen-specific cytotoxic T-cell responses.
Our multidisciplinary research team collaborates with several universities and research institutes across the world.
Our Product
DermaVir®
Our lead product candidate DermaVir® is designed to boost natural immune responses to kill HIV-infected cells in patients with compromised immunity. As current antiretroviral therapy is incapable of killing HIV-infected cells in the reservoirs or providing a cure, we believe DermaVir® has the potential to be a new state-of-the-art HIV/AIDS treatment.
Offices
Budapest
GI.HU Ltd, the Hungarian subsidiary of Genetic Immunity, Inc., has been granted the rights to therapeutic vaccine research, development, and production. Our company has developed its organization and quality control system accordingly, cooperating with several important universities and contracted manufacturing partners. In line with the guidelines and principles of Good Manufacturing Practice (GMP) and Investigational Medicinal Products (IMPs) for human use, we plan to release clinical batches of therapeutic vaccines in the European Union.